Information Density: Genentech (PERJETA) – Signal Evidence & AI Readability

I’m talking to my doctor about PERJETA + Herceptin® (trastuzumab)-based therapy for my HER2+ breast cancer.
[H1] I’m all in.

Learn More

I’m talking to my doctor about PERJETA + Herceptin® (trastuzumab)-based therapy for my HER2+ breast cancer.
[H1] I’m all in.

Learn More

[IMG: Injection needle icon]

An injection option
Discover another treatment — an injection that's given in minutes.

Learn More

Starting the conversation
Questions to ask your doctor before and during treatment with PERJETA + Herceptin-based therapy

Financial resources
Access Solutions is here to help you get the treatment you need.

Perjeta® (pertuzumab) is a prescription medicine used with trastuzumab and chemotherapy designed to treat HER2-positive breast cancer before surgery (neoadjuvant treatment) in adults with HER2-positive for locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen, and after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer with high risk of recurrence. Perjeta is also approved in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease. Perjeta works by targeting the HER2 receptor on cancer cells, preventing the cells from growing and spreading.
Perjeta is given through an IV infusion in a healthcare setting. The initial dose is 840 mg infused over 60 minutes, followed every three weeks by a dose of 420 mg infused over 30-60 minutes.
Serious side effects of Perjeta include heart problems, death of an unborn baby, and birth defects. Perjeta should not be used in patients who are allergic to Perjeta or to any of the ingredients in Perjeta. Other possible serious and sometimes fatal side effects include infusion-related reactions and severe allergic reactions. The most common side effects of Perjeta when given with trastuzumab and chemotherapy include constipation, damage to the nerves, nausea, vomiting, diarrhea, low levels of red and white blood cells, thrombocytopenia, weakness or feeling tired, rash, hair loss, headache, mouth sores or blisters, and muscle pain. Talk to your doctor about any and all side effects you experience.

[H4]
Important Safety Information

Back to Top

[H2] What is PERJETA?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and chemotherapy for:
Use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received prior anti-HER2 therapy or chemotherapy for metastatic breast cancer.

[H3] What are the possible side effects of PERJETA?
PERJETA may cause serious side effects, including:
PERJETA can cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
Your doctor will run tests to monitor your heart function before and during treatment
Based on these tests, your treatment may be interrupted or discontinued
Contact a health care professional immediately if you experience any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PERJETA during pregnancy can cause the death of an unborn baby and birth defects
Your doctor will verify your pregnancy status before treatment begins
Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
If you think you may be pregnant, you should contact your healthcare provider immediately
If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA with trastuzumab, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

[H3] Who should not take PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.

[H3] What are the other possible side effects of PERJETA?
Serious side effects of PERJETA may also include:

Infusion-related reactions: PERJETA is given as an infusion. PERJETA can cause serious infusion-related reactions, some fatal. When given alone, the most common infusion-related reactions were fever, chills, fatigue, headache, weakness, hypersensitivity, and vomiting. When given with trastuzumab and docetaxel, the most common infusion-related reactions were fatigue, altered taste, hypersensitivity, muscle pain, and vomiting

Severe allergic reactions: PERJETA can cause hypersensitivity reactions, including anaphylaxis and fatal events. Contact a health care professional immediately if you experience any of the following symptoms: swelling of the face, lips or tongue, trouble breathing, or chest pains

[H3] The most common side effects of PERJETA include:
The most common side effects of PERJETA when given with trastuzumab and chemotherapy prior to surgery for early breast cancer include:
Constipation
Damage to the nerves (numbness, tingling, pain in hands/feet)
Diarrhea
Fatigue
Hair loss
Headache
Decreased red blood cell counts, white blood cell counts, and platelet counts
Mouth sores or blisters
Nausea
Muscle pain
Vomiting
Weakness
The most common side effects of PERJETA when given with trastuzumab and chemotherapy after surgery for early breast cancer include:
Diarrhea
Nausea
Hair loss
Fatigue
Damage to the nerves (numbness, tingling, pain in hands/feet)
Vomiting
The most common side effects of PERJETA when given with trastuzumab and docetaxel for metastatic breast cancer include:
Diarrhea
Hair loss
Low levels of white blood cells with or without fever
Nausea
Fatigue
Rash
Damage to the nerves (numbness, tingling, pain in hands/feet)

Side effects may vary based on chemotherapy regimen. These are not all the possible side effects of PERJETA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-877-436-3683.
Before you take PERJETA, tell your healthcare provider about all of your medical conditions, including if you:
Have a history of heart disease
Are pregnant or plan to become pregnant. PERJETA can harm your unborn baby
Are breastfeeding or plan to breastfeed. It is not known if PERJETA passes into your breastmilk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects.

[H1] Treatment for HER2+ early breast cancer

[H1] Treatment for HER2+ early breast cancer

[H2] Knowing more about HER2+ early breast cancer
A diagnosis of HER2* positive (HER2+) breast cancer can be overwhelming. We want to help you learn more about your early breast cancer treatment.
In early breast cancer, the cancer starts in the breast but has not spread to other parts of the body. However, cancer cells may also be in nearby glands called lymph nodes.
PERJETA is a targeted cancer treatment that can be started before surgery (neoadjuvant) and may be started or continued after surgery (adjuvant). It is given in combination with a medication called Herceptin® (trastuzumab) and chemotherapy.
*HER2 stands for human epidermal growth factor receptor 2. The results from a HER2 test are needed to know if your breast cancer is HER2+.

[IMG: Injection needle icon]

An injection option
Discover another treatment — an injection that's given in minutes.

Learn More

[IMG: Woman icon]

Treatment before surgery
Learn about PERJETA + Herceptin-based therapy prior to surgery for HER2+ early breast cancer.

Neoadjuvant treatment

[IMG: Woman icon]

Treatment after surgery
Take a closer look at PERJETA + Herceptin-based therapy following surgery for HER2+ early breast cancer.
Adjuvant treatment

[IMG: IV bag icon]

How treatment is given
Understand how PERJETA + Herceptin-based therapy is given and possible side effects.

About the infusion

[H4]
Important Safety Information

Back to Top

[H2] What is PERJETA?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and chemotherapy for:
Use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received prior anti-HER2 therapy or chemotherapy for metastatic breast cancer.

[H3] What are the possible side effects of PERJETA?
PERJETA may cause serious side effects, including:
PERJETA can cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
Your doctor will run tests to monitor your heart function before and during treatment
Based on these tests, your treatment may be interrupted or discontinued
Contact a health care professional immediately if you experience any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PERJETA during pregnancy can cause the death of an unborn baby and birth defects
Your doctor will verify your pregnancy status before treatment begins
Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
If you think you may be pregnant, you should contact your healthcare provider immediately
If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA with trastuzumab, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

[H3] Who should not take PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.

[H3] What are the other possible side effects of PERJETA?
Serious side effects of PERJETA may also include:

Infusion-related reactions: PERJETA is given as an infusion. PERJETA can cause serious infusion-related reactions, some fatal. When given alone, the most common infusion-related reactions were fever, chills, fatigue, headache, weakness, hypersensitivity, and vomiting. When given with trastuzumab and docetaxel, the most common infusion-related reactions were fatigue, altered taste, hypersensitivity, muscle pain, and vomiting

Severe allergic reactions: PERJETA can cause hypersensitivity reactions, including anaphylaxis and fatal events. Contact a health care professional immediately if you experience any of the following symptoms: swelling of the face, lips or tongue, trouble breathing, or chest pains

[H3] The most common side effects of PERJETA include:
The most common side effects of PERJETA when given with trastuzumab and chemotherapy prior to surgery for early breast cancer include:
Constipation
Damage to the nerves (numbness, tingling, pain in hands/feet)
Diarrhea
Fatigue
Hair loss
Headache
Decreased red blood cell counts, white blood cell counts, and platelet counts
Mouth sores or blisters
Nausea
Muscle pain
Vomiting
Weakness
The most common side effects of PERJETA when given with trastuzumab and chemotherapy after surgery for early breast cancer include:
Diarrhea
Nausea
Hair loss
Fatigue
Damage to the nerves (numbness, tingling, pain in hands/feet)
Vomiting
The most common side effects of PERJETA when given with trastuzumab and docetaxel for metastatic breast cancer include:
Diarrhea
Hair loss
Low levels of white blood cells with or without fever
Nausea
Fatigue
Rash
Damage to the nerves (numbness, tingling, pain in hands/feet)

Side effects may vary based on chemotherapy regimen. These are not all the possible side effects of PERJETA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-877-436-3683.
Before you take PERJETA, tell your healthcare provider about all of your medical conditions, including if you:
Have a history of heart disease
Are pregnant or plan to become pregnant. PERJETA can harm your unborn baby
Are breastfeeding or plan to breastfeed. It is not known if PERJETA passes into your breastmilk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects.

[H2] What is PERJETA?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and chemotherapy for:
Use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received prior anti-HER2 therapy or chemotherapy for metastatic breast cancer.

[H3] What are the possible side effects of PERJETA?
PERJETA may cause serious side effects, including:
PERJETA can cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
Your doctor will run tests to monitor your heart function before and during treatment
Based on these tests, your treatment may be interrupted or discontinued
Contact a health care professional immediately if you experience any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PERJETA during pregnancy can cause the death of an unborn baby and birth defects
Your doctor will verify your pregnancy status before treatment begins
Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
If you think you may be pregnant, you should contact your healthcare provider immediately
If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA with trastuzumab, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

[H3] Who should not take PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.

[H3] What are the other possible side effects of PERJETA?
Serious side effects of PERJETA may also include:

Infusion-related reactions: PERJETA is given as an infusion. PERJETA can cause serious infusion-related reactions, some fatal. When given alone, the most common infusion-related reactions were fever, chills, fatigue, headache, weakness, hypersensitivity, and vomiting. When given with trastuzumab and docetaxel, the most common infusion-related reactions were fatigue, altered taste, hypersensitivity, muscle pain, and vomiting

Severe allergic reactions: PERJETA can cause hypersensitivity reactions, including anaphylaxis and fatal events. Contact a health care professional immediately if you experience any of the following symptoms: swelling of the face, lips or tongue, trouble breathing, or chest pains

[H3] The most common side effects of PERJETA include:
The most common side effects of PERJETA when given with trastuzumab and chemotherapy prior to surgery for early breast cancer include:
Constipation
Damage to the nerves (numbness, tingling, pain in hands/feet)
Diarrhea
Fatigue
Hair loss
Headache
Decreased red blood cell counts, white blood cell counts, and platelet counts
Mouth sores or blisters
Nausea
Muscle pain
Vomiting
Weakness
The most common side effects of PERJETA when given with trastuzumab and chemotherapy after surgery for early breast cancer include:
Diarrhea
Nausea
Hair loss
Fatigue
Damage to the nerves (numbness, tingling, pain in hands/feet)
Vomiting
The most common side effects of PERJETA when given with trastuzumab and docetaxel for metastatic breast cancer include:
Diarrhea
Hair loss
Low levels of white blood cells with or without fever
Nausea
Fatigue
Rash
Damage to the nerves (numbness, tingling, pain in hands/feet)

Side effects may vary based on chemotherapy regimen. These are not all the possible side effects of PERJETA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-877-436-3683.
Before you take PERJETA, tell your healthcare provider about all of your medical conditions, including if you:
Have a history of heart disease
Are pregnant or plan to become pregnant. PERJETA can harm your unborn baby
Are breastfeeding or plan to breastfeed. It is not known if PERJETA passes into your breastmilk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects.

[H1] Financial Assistance Options

No matter what type of health insurance you have, and even if you have none at all, there may be some potential options available to help you afford your medicine.

[H3] Quick Links

Genentech Oncology Co-pay Assistance Program

Independent Co-pay Assistance Foundations

Genentech Patient Foundation

Use our financial assistance tool to see which programs may be right for you. If you would rather talk through some potential options, call us at 888-249-4918 (6AM-5PM PST, Monday through Friday).

Get started

If you have insurance coverage and need help affording PERJETA, these programs may help:

[H3] Genentech Oncology Co-pay Assistance Program

[IMG: Co-pay Card Assistance]

With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for PERJETA. Co-pay assistance of up to $25,000 is provided per calendar year.
You may be eligible if you:
Are taking PERJETA for an FDA-approved use
Are 18 years of age or older or have a Legally Authorized Person over the age of 18 to manage the program
Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
Live and receive treatment in the United States or U.S. Territories
Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
Do not use a state or federal healthcare plan to pay for your medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE
The Co-pay Program (“Program”) is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. The Program is not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Program.
Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient’s out-of-pocket expenses for the Genentech medicine.
All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply with Genentech Program Terms and Conditions. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.
Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.
View full TERMS AND CONDITIONS.
Apply for the Genentech Oncology Co-pay Assistance Program

Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace. Medicare and Medicaid are not considered commercial insurance.

[H3] Independent Co-pay Assistance Foundations

[IMG: Independent Co-pay Assistance]

An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation.

These foundations may be able to help. Please check their websites for up-to-date information.

Organizations for Oncology (Breast)

CancerCare Co-Payment Assistance Foundation
Good Days from CDF
Patient Access Network Foundation (PANF)
Patient Advocate Foundation (PAF)
The Assistance Fund, Inc.
The HealthWell Foundation

These organizations are independent of Genentech and may require you to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information you have provided to us.

Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.

If you have financial difficulty or do not have insurance coverage and need help affording PERJETA, this program may help:

[H3] Genentech Patient Foundation

[IMG: Genentech Patient Foundation]

The Genentech Patient Foundation gives free PERJETA to people who have been prescribed this medicine and don’t have insurance or that have financial concerns and meet certain eligibility criteria.
You may be eligible if your insurance coverage and income match one of these situations:
Uninsured patients with incomes under $150,000
Insured patients without coverage for PERJETA with incomes under $150,000
Insured patients with coverage for a Genentech medicine:
With an out-of-pocket maximum set by their health insurance plan that exceeds 7.5% of their household income
Who have pursued other forms of financial assistance
With household size and income within certain guidelines

[H4] Enrollment Process for the Genentech Patient Foundation
If you meet the criteria and would like to enroll:

To get started:
Complete the Patient Consent Form, which is available in English and Spanish, below:
Patient Consent Form
Formulario de Consentimiento del Paciente
Once you have completed the Patient Consent Form, please let your doctor's office know that you are applying for assistance with the Genentech Patient Foundation. Your doctor will have to complete another form called the Prescriber Foundation Form. Both forms are required. We must have both the Patient Consent Form and the Prescriber Foundation Form before we can help you.

What to expect next:
The request will be processed within five business days upon receipt of both required forms.
You and your provider will be contacted to discuss the application outcome and any next steps.

If you have any questions about the criteria, please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST).

Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

[H4] Not sure which programs may be able to help you? We'll walk you through some potential options with the financial assistance tool.

Get started

Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace. Medicare and Medicaid are not considered commercial insurance.

Public insurance: A health insurance plan you get from the federal or state government. This includes Medicare, Medicaid, TRICARE and DoD/VA insurance.

For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.

The Co-pay Program (“Program”) is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. The Program is not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Program. The Program is not valid for Genentech medicines that are eligible to be reimbursed in their entirety by private insurance plans or other programs.
Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details available on the Program Website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient’s out-of-pocket expenses for the Genentech medicine. The maximum Program benefit will reset every January 1st. The Program is not health insurance or a benefit plan. The patient’s non-governmental insurance is the primary payer. The Program does not obligate the use of any specific medicine or provider. Patients receiving assistance from charitable free medicine programs (such as the Genentech Patient Foundation) or any other charitable organizations for the same expenses covered by the Program are not eligible. The Program benefit cannot be combined with any other rebate, free trial or other offer for the Genentech medicine. No party may seek reimbursement for all or any part of the benefit received through the Program.
The Program may be accepted by participating pharmacies, physicians’ offices or hospitals. Once a patient is enrolled, the Program will honor claims with a date of service that precedes the Program enrollment date up to 180 days. Claims must be submitted within 365 days from the date of service unless otherwise indicated. Use of the Program must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physicians’ offices and hospitals are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. Programs’ benefits may not be sold, purchased, traded or offered for sale.
The patient or their guardian must be 18 years of age or older to receive Program assistance. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. Eligible patients will be automatically re-enrolled in the Program on an annual basis each January 1st. Eligible patients will be removed from the Program after 3 years of inactivity (e.g., no claims submitted in a 3-year timeframe). Patients who choose reimbursement via virtual debit card will have access to the patient’s funds as long as the patient's virtual debit card is valid and the patient is active in the Program. Once a patient's virtual debit card has expired and they are no longer active in the program, the funds will be removed from the virtual debit card. Program eligibility and automatic re-enrollment are contingent upon the patient’s ability to meet all requirements set forth by the Program. Healthcare providers may not advertise or otherwise use the Program as a means of promoting their services or Genentech medicines to patients.
The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply with Genentech Program Terms and Conditions. Genentech reserves the right to rescind, revoke or amend the Program without notice at any